drugset / Trial / NCT02737605
A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of the study is to assess the effects of esketamine on QT/QTc intervals and electrocardiogram (ECG) morphology at therapeutic exposures of esketamine and noresketamine (intranasal administration) and supratherapeutic exposures of esketamine (intravenous administration) in healthy adults.
Timeline
- Start
- 2016-07-01
- Primary completion
- 2017-02-23
- Completion
- 2017-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esketamine | Other / unclassified | 0.8 mg/kg | Intranasal |
| Subject | Esketamine | Other / unclassified | 84 mg | Intranasal |
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.